CY-09 effectively inhibits IL-1β production and the influx of neutrophils in the monosodium urate (MSU) injection-induced gout model, suggesting CY-09 plays a vital role in blocking NLRP3 inflammasome activation in vivo. CY-09 treatment can also suppress noncanonical NLRP3 activation induced by cytoplasmic LPS in BMDM [19]. This evidence concerns the gene NLRP3 and gout.